Targeted Therapy & Precision Oncology
Part of Healthcare - Oncology
 LLY | Eli Lilly & Co. | $1.1t | $1174.75 | +0.6% | 2.2M |
 RVMD | Revolution Medicines, Inc. Common Stock | $39.8b | $184.55 | +3.9% | 1.5M |
 INCY | Incyte Genomics Inc | $22.6b | $117.64 | +0.5% | 1.6M |
 JAZZ | Jazz Pharmaceuticals, Inc. | $15.1b | $248.12 | +2.2% | 390.2K |
 EXEL | Exelixis Inc | $13.7b | $55.80 | +0.4% | 1.7M |
 NUVL | Nuvalent, Inc. Class A Common Stock | $9.8b | $123.96 | 0.0% | N/A |
 CORT | Corcept Therapeutics Inc. | $9.3b | $90.55 | +0.8% | 855.8K |
 HALO | Halozyme Therapeutics, Inc. | $9.3b | $77.80 | +0.3% | 1.1M |
 COGT | Cogent Biosciences, Inc. Common Stock | $6.6b | $38.45 | +3.0% | 1.6M |
 ERAS | Erasca, Inc. Common Stock | $5.7b | $18.77 | +0.7% | 6.0M |
 CELC | Celcuity Inc. Common Stock | $5.1b | $89.25 | +0.2% | 1.2M |
 TNGX | Tango Therapeutics, Inc. | $5.1b | $29.02 | +3.1% | 2.0M |
 RLAY | Relay Therapeutics, Inc. Common Stock | $4.1b | $19.89 | +2.8% | 1.8M |
 IDYA | IDEAYA Biosciences, Inc. Common Stock | $3.6b | $36.75 | +0.2% | 793.2K |
 ELVN | Enliven Therapeutics, Inc. Common Stock | $3.6b | $53.65 | +4.5% | 730.5K |
 NRIX | Nurix Therapeutics, Inc. Common stock | $2.5b | $23.13 | +0.2% | 643.3K |
 IMNM | Immunome, Inc. | $2.4b | $22.23 | +0.5% | 540.5K |
 BHVN | Biohaven Ltd. | $2.2b | $15.39 | +9.0% | 3.2M |
 DAWN | Day One Biopharmaceuticals, Inc. Common Stock | $2.2b | $21.52 | -0.0% | 3.0M |
 GLUE | Monte Rosa Therapeutics, Inc. Common Stock | $2.0b | $25.00 | +6.0% | 1.1M |
 NUVB | Nuvation Bio Inc. | $2.0b | $5.83 | +2.8% | 3.3M |
 ZYME | Zymeworks Inc. | $1.9b | $24.25 | 0.0% | 350.4K |
 TYRA | Tyra Biosciences, Inc. Common Stock | $1.9b | $31.91 | +1.6% | 462.0K |
 URGN | UroGen Pharma Ltd. Ordinary Shares | $1.8b | $40.52 | +0.6% | 1.1M |
 NVCR | NovoCure Limited Ordinary Shares | $1.8b | $15.91 | -3.1% | 668.9K |
 VIR | Vir Biotechnology, Inc. Common Stock | $1.7b | $9.52 | +0.4% | 1.5M |
 AVBP | ArriVent BioPharma, Inc. Common Stock | $1.6b | $33.07 | +0.9% | 767.4K |
 DMRA | Damora Therapeutics, Inc. Common Stock | $1.6b | $31.46 | +4.7% | 437.3K |
 ORIC | Oric Pharmaceuticals, Inc. Common Stock | $1.1b | $10.84 | -0.1% | 1.5M |
 OLMA | Olema Pharmaceuticals, Inc. Common Stock | $1.1b | $11.10 | +3.5% | 1.2M |
 KURA | Kura Oncology, Inc. | $1.0b | $10.98 | -0.3% | 655.0K |
 GERN | Geron Corp | $0.8b | $1.44 | +1.4% | 4.1M |
 RLMD | Relmada Therapeutics, Inc. Common Stock | $0.7b | $5.48 | -4.3% | 3.1M |
 RIGL | Rigel Pharmaceuticals Inc. (New) | $0.7b | $40.53 | -2.5% | 153.7K |
 MNPR | Monopar Therapeutics Inc. Common Stock | $0.6b | $110.45 | +1.6% | 256.9K |
 BBOT | BridgeBio Oncology Therapeutics, Inc. Common Stock | $0.6b | $8.56 | +3.1% | 255.2K |
 STRO | Sutro Biopharma, Inc. | $0.6b | $23.50 | -1.0% | 282.4K |
 ARVN | Arvinas, Inc | $0.5b | $8.01 | -0.4% | 417.1K |
 CCCC | C4 Therapeutics, Inc. | $0.5b | $3.71 | +3.5% | 2.3M |
 NVCT | Nuvectis Pharma, Inc. Common Stock | $487.8m | $19.39 | +2.9% | 311.3K |
 DCTH | Delcath Systems Inc | $434.6m | $12.81 | +0.1% | 268.8K |
 PRLD | Prelude Therapeutics Incorporated | $424.5m | $4.20 | +0.7% | 146.0K |
 PBYI | PUMA BIOTECHNOLOGY INC | $412.8m | $8.53 | +1.5% | 222.3K |
 ZNTL | Zentalis Pharmaceuticals, Inc. Common Stock | $345.3m | $5.07 | +11.4% | 3.5M |
 VSTM | Verastem, Inc. | $335.7m | $5.93 | +5.0% | 3.3M |
 IMRX | Immuneering Corporation Class A Common Stock | $322.8m | $4.77 | -3.1% | 1.3M |
 TLSI | TriSalus Life Sciences, Inc. Common Stock | $279.4m | $4.29 | -1.6% | 116.3K |
 WHWK | Whitehawk Therapeutics, Inc. Common Stock | $226.5m | $3.94 | 0.0% | 236.5K |
 KPTI | Karyopharm Therapeutics Inc. | $221.4m | $9.11 | +1.5% | 175.9K |
 PYXS | Pyxis Oncology, Inc. Common Stock | $190.7m | $2.35 | +6.3% | 356.0K |